Methylphenidate Transdermal System

  title={Methylphenidate Transdermal System},
  author={Vanessa R. Anderson and Lesley J. Scott},
Abstract▴ The methylphenidate transdermal system (MTS) patch is approved by the US FDA for use in children aged 6–12 years with attention-deficit hyperactivity disorder (ADHD). This delivery system permits sustained absorption of the drug through the skin and into the bloodstream. Methylphenidate (MPH) is a CNS agent thought to act on dopamine and noradrenaline (norepinephrine) pathways and thereby blocks the reuptake of these neurotransmitters into the presynaptic neuron.▴ In children with… Expand
Methylphenidate Transdermal System
Methylphenidate transdermal system was generally well tolerated in adolescents with ADHD and the vast majority of treatment-emergent adverse events were of mild to moderate severity in both the short-term core trial and the longer-term extension study. Expand
Investigation Lithium Chloride Role in Improving the Infertility from Methylphenidate (Ritalin) in Wistar Male Rats
Methylphenidate Hydrochloride (MPH) the more for treatment Attention Deficit/Hyperactivity Disorder (ADHD) had prescribed. Lithium salts using frequently for treatment madness (mania), bipolarExpand
Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients.
OBJECTIVE As dopamine functioning varies by sex and age it might be expected that the effects of methylphenidate or amfetamine, the psychostimulants used for the treatment of Attention DeficitExpand
A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.
  • L. Briars, Timothy J. Todd
  • Medicine
  • The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
  • 2016
This review focuses on the clinical use of psychostimulant medication in children and adolescents and the pharmacodynamic and pharmacokinetic differences between the newest long-acting formulations as well as commonly encountered adverse drug reactions. Expand
Improving Drug Delivery in Paediatric Medicine
Current advances in paediatric drug development include interesting new drug delivery concepts such as fast-dissolving drug formulations, including buccal films and wafers, and multiparticulate dosage forms. Expand
Percutaneous penetration of drugs applied in transdermal delivery systems: An in vivo based approach for evaluating computer generated penetration models.
For more than half of the drugs applied in TDS, the predicted flux by the mathematical models was an underestimation compared to the flux calculated with the experimental in vivo data, and the flux was over- or underestimated by a factor 10-100. Expand
Risiko, Risikomanagement und Unternehmensüberwachung
Samtliche zukunftsgerichteten Entscheidungen eines Unternehmens bergen Risiken in sich, da sie unter Unsicherheit getroffen werden. Der Begriff des Risikos wird in den Wirtschaftswissenschaften mitExpand


Extended- Release Methylphenidate (Ritalin® LA)
Extended-release methylphenidate improved both inattention and hyperactivity symptoms and was effective in children with combined- (inattentive and hyperactive/impulsive) type or predominantly inattentively-type ADHD. Expand
A dose-ranging study of a methylphenidate transdermal system in children with ADHD.
  • W. Pelham, M. Manos, +11 authors G. Morse
  • Psychology, Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2005
There does not appear to be a substantial effect of application time on total daily functioning in this setting; further controlled time-course studies will be necessary to evaluate the question of morning onset fully. Expand
Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
Low doses of methylphenidate--even lower than in previous studies--yielded enhanced effects in combination with behavior modification, and combined treatment was superior to either treatment alone. Expand
Pharmacokinetics and Clinical Effectiveness of Methylphenidate
It is difficult to predict which children will have a favourable response to methylphenidate, and therefore dosage must be titrated for optimal effect and avoidance of toxicity in each child, and further studies of the relationship between the pharmacokinetic and pharmacodynamic properties are required to allow the development of optimal dosage regimens. Expand
Stimulant medications : Current knowledge and unmet needs in pediatrics psychopharmacology
Objective: To review the short- and long-term safety and efficacy of stimulants for the treatment of children with attention-deficit/hyperactivity disorder (ADHD). Method: A Medline search wasExpand
A Randomized, Double-Blind, Placebo-Controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children With ADHD
Time course and therapeutic effects of MTS suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD. Expand
Pharmacokinetic and Pharmacodynamic Drug Interactions in the Treatment of Attention-Deficit Hyperactivity Disorder
Psychostimulant pharmacology is examined, reported drug-drug interactions are summarized, underlying pharmacokinetic and pharmacodynamic considerations for interactions are explored and it appears that these agents may be safely coadministered. Expand
Stimulant medications.
Current evidence indicates that stimulants show efficacy and safety in studies lasting up to 24 months and there is no conclusive evidence that careful therapeutic use of these medications is harmful. Expand
Ritalin LA ® ( methylphenidate hydrochloride ) extended-release capsules
    DESCRIPTION Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. Ritalin LA ® (methylphenidate hydrochloride) extended-release capsules is an extended-release formulation ofExpand
    Psychopharmacology of ADHD: children and adolescents.
    Concerns regarding potential cardiotoxicity have tempered the enthusiasm for both tricyclic antidepressants, but newer antidepressants such as bupropion and venlafaxine may hold promise as treatments for ADHD. Expand